What It Was For: Andexxa was used in emergency situations to reverse the blood-thinning effects of popular anticoagulants like Eliquis (apixaban) and Xarelto (rivaroxaban) in patients with life-threatening or uncontrolled bleeding .
The Risk: A required post-marketing study (ANNEXA-I) revealed alarming safety signals. Compared to usual care, patients treated with Andexxa had:
A doubling of thrombosis (blood clot) rates (14.6% vs. 6.9%).
Higher rates of thrombosis-related deaths (2.5% vs. 0.9%).
Earlier onset of thrombotic events .
What This Means for Patients: This drug is no longer available for new patients in the U.S. . If you are a healthcare provider, you must find alternative strategies for anticoagulation reversal. For patients, this highlights how post-marketing surveillance is critical for confirming a drug's safety.
3. Common NSAIDs (Ibuprofen, Naproxen): Strengthened Heart Attack & Stroke Warning
It's not just new or specialty drugs that carry risks. The FDA has strengthened the warning labels for widely available pain relievers like non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) .
Affected Drugs: This includes both prescription and over-the-counter NSAIDs such as ibuprofen (e.g., Advil, Motrin), naproxen (e.g., Aleve), diclofenac, and celecoxib (Celebrex) .
The Risk:
NSAIDs can increase the chance of a serious heart attack or stroke, which can be fatal. This risk can occur as early as the first weeks of use and may increase with longer use and higher doses .
The risk exists for people with or without heart disease, but those with existing conditions are at a higher baseline risk .
They also increase the risk of heart failure .
What This Means for Patients:
Use the lowest effective dose for the shortest possible time .
Be aware that many OTC cold, flu, and sleep aids also contain NSAIDs, so read labels carefully to avoid taking too much .
Seek immediate medical attention if you experience symptoms like chest pain, shortness of breath, sudden weakness on one side, or slurred speech .
If you take low-dose aspirin for heart protection, be aware that some NSAIDs (like ibuprofen and naproxen) can interfere with its protective effect .
🔍 Other Recent Recalls & Alerts (Manufacturing Issues vs. Inherent Drug Risk)
It's important to distinguish between a drug being inherently risky and a specific batch being poorly manufactured. Here are recent recalls due to quality control issues:
1. Icosapent Ethyl (Generic Vascepa) – Recalled for Leakage
In early 2026, Zydus Pharmaceuticals recalled over 20,000 bottles of generic icosapent ethyl (a triglyceride-lowering medication) because the capsules were leaking due to oxidation .
The Risk: This is not a new risk from the drug itself. The concern is that leaking capsules could reduce the drug's effectiveness (meaning it might not lower your triglycerides as well) or cause stomach upset . The FDA classified this as a Class II recall, meaning the probability of serious adverse health consequences is remote .
What This Means for Patients: If you have one of the affected lot numbers, contact your pharmacy. However, stopping your medicine could be more harmful, so the FDA advises not to stop taking it without a replacement .
2. Atorvastatin (Generic Lipitor) – Recalled for Failed Dissolution
In late 2025, over 140,000 bottles of generic atorvastatin calcium were recalled by Ascend Laboratories due to "failed dissolution specifications" . This means the tablets might not dissolve properly in the body.
